GlassScriptPhysician profile
Neerja Kaul
NPI 1518946722
$541.34
in general payments reported to CMS, 2019-2025
11 companies · $23.08 in 2025
The $23.08 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $395 · 2020: $49.60 · 2024: $73.21 · 2025: $23.08.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $96.29.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $96.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $170.21 | 2019-2024 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $64.40 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $53.08 | 2019 | |
| Allergan, INC. | $51.81 | 2019-2020 | |
| La Jolla Pharmaceutical Company | $51.80 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $34.46 | 2024 | Lifevest |
| Merck Sharp & Dohme LLC | $31.75 | 2019 | |
| Pfizer INC. | $29.79 | 2019 | |
| W. L. Gore & Associates, INC. | $23.08 | 2025 | Gore Cardioform Septal Occluder |
| Smith+Nephew, INC. | $18.93 | 2024 | Collagenase Santyl |
| Astrazeneca Pharmaceuticals LP | $12.03 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Neerja Kaul listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.